Article
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Antiviral therapy - 1 Jan 2013
Takkenberg R Bart, Jansen Louis, de Niet Annikki, Zaaijer Hans L, Weegink Christine J, Terpstra Valeska, Dijkgraaf Marcel G W, Molenkamp Richard, Jansen Peter L M, Koot Maarten, Rijckborst Vincent, Janssen Harry L A, Beld Marcel G H M, Reesink Hendrik W
Abstract excerpt
BACKGROUND: In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir. METHODS: We treated 92 chronic hepatitis B patients (44 hepatitis B e antigen [HBeAg]-positive and 48 HBeAg-negative) with HBV DNA > 100,000 copies/ml (> 17,182 IU/ml) with PEG-IFN and adefovir for 48 weeks and followed them...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.